News
Prescription pills

United Drug posts €66.2m profits

The pharmaceutical sector supplier has reported pre-tax profits of €66.2 million in the period to September 30, an increase of 17 percent.

An AstraZeneca facility is seen in this undated handout photo. REUTERS/Newscast/Handout

AstraZeneca to cut jobs and halts generic asthma drug

Anglo-Swedish drugmaker AstraZeneca plans 1,400 job cuts and is closing three plants around Europe as it joins others in the sector tackling increased competition and cost pressures.

Elan logo

Elan names Paya new President

Elan Corp plc, the Dublin-based drug company, has appointed Carlos V Paya as President, effective November 25.

AstraZeneca logo

AstraZeneca alters earnings forecast

Anglo-Swedish drugmaker AstraZeneca saw shares plummet 11 percent on Wednesday after it said its full-year earnings per share (EPS) would be at the lower end of its previously stated range.

Yellow prescription pills

United Drug acquires TSL for £20.1m

Dublin-based United Drug plc has acquired the entire issued share capital of The Specials Laboratory Holdings Ltd (TSL) for a consideration of £20.1 million.

Blue syringe

Merck KGaA working with EU on Raptiva drug

Drugmaker Merck KGaA, which markets Genentech’s psoriasis drug Raptiva, has said it is working with European Union regulators following the death of a second patient.

Unilever abandons Phytopharm weight-loss product

Consumer goods giant Unilever dealt a blow to drugs-from-plants firm Phytopharm on Friday by abandoning plans to develop its Hoodia product as a functional food to help people lose weight.

Pfizer logo

Pfizer to build UK stem cell centre

Pfizer Inc, the world’s largest drug company has announced plans to spend up to US$60 million (£41 million) on a research centre in Cambridge.

Roche Avastin drug increases survival in lung cancer patients

Roche Holding AG has stated that its drug Avastin extended the lives of patients with one of the most common types of lung cancer by four months.

Addex logo

GSK increases stake in Addex

GlaxoSmithKline, Europe's largest drugmaker, has increased its stake in Addex Pharmaceuticals to five percent, the biotechnology firm said on Wednesday, November 12.

Signage is pictured on the company headquarters of GlaxoSmithKline in west London July 21, 2008. REUTERS/Toby Melville

Glaxo steps up job cuts with UK factory closure

GlaxoSmithKline , the world's second biggest drugmaker, said on Tuesday it planned to close its Dartford manufacturing site in south-east England by 2013 with the loss of 620 jobs.

Nobel Biocare to acquire Canada’s BioCad

Swiss dental implant maker Nobel Biocare said this morning, November 11, it is buying privately-owned prosthetics software design company BioCad for €26 million.

Crestor cuts risk of heart disease, study finds

A large-scale study of AstraZeneca plc's anti-cholesterol drug, Crestor, has been shown to cut heart-attack risk even for people without high cholesterol, the drugmaker said.

Roche’s Tarceva drug delays advance of lung cancer, study shows

Swiss drugmaker Roche said today, November 7, a Phase III study has confirmed that its drug Tarceva delays the advance of lung cancer when given immediately after chemotherapy.

Smith & Nephew Q3 earnings fall short

Europe's biggest medical device company Smith & Nephew posted third-quarter earnings short of analyst forecasts on Thursday and suspended share buybacks, sending its stock sharply lower.

Sanofi-Aventis to discontinue all trials of Acomplia

French drugmaker Sanofi-Aventis announced yesterday, November 5, it would discontinue all clinical trials involving its troubled anti-obesity pill Acomplia.

A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008. REUTERS/Toby Melville

Glaxo cutting 1,000 jobs in U.S.

GlaxoSmithKline , the world's second-biggest drugmaker, is cutting approximately 1,000 U.S. sales jobs by the end of 2008 as it reorganises the operation to compete in an increasingly tough market.

AstraZeneca’s head of drug development to retire

John Patterson, AstraZeneca plc's head of drug development, will retire from the company next March.

Nobel Biocare profit down 62%

Swiss dental implant maker Nobel Biocare posted a lower-than-expected net profit in the third quarter as customers cut back on expensive dental treatments.

Four Seasons inks new standstill agreement with creditors

Senior creditors of Four Seasons Healthcare have extended a “standstill” deal over the care home group’s debt, giving them until January 22 to agree a restructuring of its £1.5 billion debt load.

AstraZeneca Chief Executive David Brennan in Boston, May 6, 2008. REUTERS/Brian Snyder

AstraZeneca third quarter beats forecasts

Drugmaker AstraZeneca suspended share buybacks on Thursday to give more scope for acquisitions as third-quarter forecasts beat expectations and earnings forecasts for the full year were increased.

Cigna profit drops 53 percent, sees loss ahead

Health insurer Cigna Corp posted a 53 percent decline in third-quarter profit on Thursday, hurt by losses stemming from the market volatility, and said it expected to post a fourth-quarter loss related to its death benefits business.

Elan shares dip in US over Tysabri scare

Shares in Elan Corp dropped 28 percent in New York after the Irish drugmaker reported a third case of the brain disease progressive multifocal leukoencephalopathy (PML) in a patient taking its multiple scelroris drug Tysabri.

Swiss authorities approve Novartis blood pressure drug

Drugmaker Novartis AG said, October 29, Swiss authorities have approved its blood pressure treatment Rasilez HCT.

Anglia Healthcare acquired by Sunquest

Anglia Healthcare Systems Ltd have said it has been acquired by Tuscan-based Sunquest Information Systems Inc.

Drug discovery could be hit by credit crunch

The credit crunch could seriously delay the discovery and production of many new medicines, a British expert warned on Monday, October 27.

Acomplia should be withdrawn, European authorities

European authorities said on Thursday, October 23, Sanofi-Aventis's anti-obesity drug Acomplia should be withdrawn from the market because of side effects including suicide and depression.

PPF raises stake in Zentiva

Czech privately owned PPF Group NV raised its voting rights stake in Zentiva to 24.26 percent, a filing with a Dutch regulator AFM showed on Thursday, October 23.

A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008. REUTERS/Toby Melville

Weak pound helps Glaxo third-quarter results

GlaxoSmithKline's earnings beat analyst forecasts on Wednesday, helped by a weak pound, and the world's second biggest drugmaker said it was hunting for acquisition bargains thrown up by the credit crunch.

Apitope to quit UK

The British biotechnology company Apitope has said that it is to shift its headquarters to Belgium after its failure to find a UK investor.

Actelion Q3 beats forecasts

Swiss biotech company Actelion Ltd reported a 26 percent jump in third quarter net profit, boosted by strong sales of key drug Tracleer.

Novartis Q3 profit rises 32%

Novartis AG said today, October 20, its net profit rose to US$2.08 billion, helped by strong sales of its top-selling blood pressure drug Diovan.

Bayer wins EU approval for Qlaira

Bayer AG said it has won European approval for its contraceptive pill Qlaira, which the chemical and pharmaceutical maker expects to generate sales of up to €500 million per year.

GSK makes acquisition in Egypt

GlaxoSmithKline plc will acquire the Egyptian mature products business of Bristol Myers Squibb (BMS) for US$210 (£125) million, in a move to further extend its pharmaceutical portfolio in emerging markets.

Glaxo will lead in Egypt after purchase

GlaxoSmithKline is buying the Egyptian mature products business of Bristol-Myers Squibb Co for $210 million (120 million pounds), to extend the drug company's recent expansion into emerging markets.

Bayer to delist from Tokyo Exchange

Bayer AG said on Wednesday, October 15, it planned to delist its shares from the Tokyo Stock Exchange (TSE) because the trading volumes there no longer justified the costs.

Durex logo

SSL International sees H1 sales rise 22%

SSL International plc posted first half sales of over £320 million as business continued to show encouraging signs.

Abbott announces share repurchase

Abbott Laboratories said its board had authorized a new program to repurchase up to US$5 billion of the company's common stock.

Boston Scientific shares slump to 52-week low

Shares in Boston Scientific Corp dropped to a 52-week low on Friday, October 10, triggered by the collapse of Lehman Brothers and the large scale share sell-off by its founders.

Acino Plavix generic has potential sales of €500m - Chairman

Acino Holding AG sees total potential sales for its generic version of Sanofi-Aventis SA's Plavix at €500 million, its Chairman said in an interview published today, October 13.

Nobel Biocare shares in record fall

Nobel Biocare Holding AG had a record fall in Swiss trading after third-quarter revenue declined and the company said it may not be able to meet its full-year guidance.

Southern Cross FY EBITDA in line with outlook

Southern Cross said today, October 10, it sees its full-year adjusted EBITDA in line with its previous guidance.

FDA approves amendments to Oxford BioMedica TroVax study

Oxford BioMedica plc said today, October 7, that the US Food and Drug Administration (FDA) had approved a series of amendments to the PHASE III TRIST study of its lead drug TroVax in renal cancer.

Tarceva

Roche gets UK approval for low-cost Tarceva

The National Institute for Health and Clinical Excellence has recommended Roche’s Tarceva for use on the National Health Service after the Swiss drugmaker agreed to cut the price of the lung cancer drug.

United Drug FY 2008 earnings to meet forecasts

United Drug plc said it will meet its targets of a double-digit increase in operating profit and earnings for the year ending September 30.

Zentiva board agrees Sanofi offer

Zentiva NV have said its board unanimously recommended that shareholders accept an all-cash bid of CZK1,150 per share by French drugmaker Sanofi-Aventis SA.

GSK may shed 6% of R&D jobs

GlaxoSmithKline plc is planning to cut up to 850 research and development jobs in Britain and the United States, in a bid to improve productivity.

Claimar not expecting to meet forecasts

In a trading update today, September 29, care services provider Claimar Care Group plc said it sees normalised full-year pretax profit at the lower end of market expectations.

MDY Healthcare smallcaps disappoint

MDY Healthcare plc said this morning, September 29, that it is less likely to invest in smaller companies after its smallcap portfolio disappointed.

Ascribe acquires WCI Consulting healthcare division

Ascribe plc has acquired WCI Healthcare for £650,000, with a further £300,000 deferred consideration to be paid in 12 months subject to performance.

Sanofi-Aventis to finalise Acambis deal

French drugmaker Sanofi-Aventis SA is set to complete the acquisition of Acambis plc today, September 25, the Financial Times has reported.

Sanofi downgraded to 'underperform' at Credit Suisse

Sanofi-Aventis SA, France's largest drugmaker, was yesterday, September 23, downgraded to “underperform” from “neutral” at Credit Suisse Group AG.

Cryo-Save predicts weaker FY results

Europe’s largest adult stem cell storage bank, Cryo-Save Group plc, warned Tuesday, September 23, that its full-year results will fall below its previous expectations.

Zentiva accepts revised Sanofi offer

Sanofi-Aventis said on Monday, September 22, that Zentiva had accepted a higher takeover offer that valued the Czech generics drugmaker at around €1.8 billion.

Sanofi-Aventis given more time to extend Zentiva bid

French drugmaker Sanofi-Aventis SA has received permission to extend its CZK30 billion bid for Czech generic-drug maker Zentiva NV.

Protherics agrees BTG’s all share offer

BTG has agreed to buy Protherics for around £218.1 million in an all share deal, the companies said this morning, September 18.

Roche VP raises stake in MedAssurant

Andre Hoffmann, Vice-President of Roche Holdings AG, is investing US$175 million in US healthcare data analysis company MedAssurant, raising his stake to 15 percent.

Gérard Le Fur

Sanofi’s Le Fur to receive big payout

Gérard Le Fur, the Chief Executive ousted from Sanofi-Aventis last week, could receive up to €8 million from the French pharmaceutical group before he stands down in December.

Nestor to sell Carewatch unit for £37m cash

NHS staff supplier Nestor Healthcare Group plc has sold its Carewatch unit to a newly incorporated company controlled by private equity partnership Lyceum Capital.

AstraZeneca unit buys global rights to SBI drug

AstraZeneca plc has entered into a licensing and collaboration agreement with SBI Biotech Co Ltd, a subsidiary of SBI Holdings Inc, to develop and commercialise the company’s anti-ILT7 protein.